tbuckley/cabot-search huggingface dataset:
A Multimodal Molecular Imaging Study Evaluates Pharmacological Alteration of the Tumor Microenvironment to Improve Radiation Response
Authors: Yoichi Takakusagi, Sarwat Naz, Kaori Takakusagi, Masahiro Ishima, Hiroshi Murata, Keisuke Ohta, Masahiko Miura, Fumio Sugawara, Kengo Sakaguchi, Shun Kishimoto, Jeeva P. Munasinghe, James B. Mitchell, Murali C. Krishna
Journal: Cancer Research (2018)

: Hypoxic zones in solid tumors contribute to radioresistance, and pharmacologic agents that increase tumor oxygenation prior to radiation, including antiangiogenic drugs, can enhance treatment response to radiotherapy. Although such strategies have been applied, imaging assessments of tumor oxygenation to identify an optimum time window for radiotherapy have not been fully explored. In this study, we investigated the effects of α-sulfoquinovosylacyl-1,3-propanediol (SQAP or CG-0321; a synthetic derivative of an antiangiogenic agent) on the tumor microenvironment in terms of oxygen partial pressure (pO2), oxyhemoglobin saturation (sO2), blood perfusion, and microvessel density using electron paramagnetic resonance imaging, photoacoustic imaging, dynamic contrast-enhanced MRI with Gd-DTPA injection, and T2*-weighted imaging with ultrasmall superparamagnetic iron oxide (USPIO) contrast. SCCVII and A549 tumors were grown by injecting tumor cells into the hind legs of mice. Five days of daily radiation (2 Gy) combined with intravenous injection of SQAP (2 mg/kg) 30 minutes prior to irradiation significantly delayed growth of tumor xenografts. Three days of daily treatment improved tumor oxygenation and decreased tumor microvascular density on T2*-weighted images with USPIO, suggesting vascular normalization. Acute effects of SQAP on tumor oxygenation were examined by pO2, sO2, and Gd-DTPA contrast-enhanced imaging. SQAP treatment improved perfusion and tumor pO2 (ΔpO2: 3.1 ± 1.0 mmHg) and was accompanied by decreased sO2 (20%-30% decrease) in SCCVII implants 20-30 minutes after SQAP administration. These results provide evidence that SQAP transiently enhanced tumor oxygenation by facilitating oxygen dissociation from oxyhemoglobin and improving tumor perfusion. Therefore, SQAP-mediated sensitization to radiation in vivo can be attributed to increased tumor oxygenation. SIGNIFICANCE: A multimodal molecular imaging study evaluates pharmacological alteration of the tumor microenvironment to improve radiation response.
Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies
Authors: Megan Othus, Mikkael A. Sekeres, Sucha Nand, Guillermo Garcia-Manero, Frederick R. Appelbaum, Harry P. Erba, Eli Estey
Journal: Leukemia (2018)
A Stem Cell-Based Screening Platform Identifies Compounds that Desensitize Motor Neurons to Endoplasmic Reticulum Stress
Authors: Sebastian Thams, Emily Rhodes Lowry, Marie-Hélène Larraufie, Krista J. Spiller, Hai Li, Damian J. Williams, Phuong Hoang, Elise Jiang, Luis A. Williams, Jackson Sandoe, Kevin Eggan, Ivo Lieberam, Kevin C. Kanning, Brent R. Stockwell, Christopher E. Henderson, Hynek Wichterle
Journal: Molecular Therapy (2018)

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease selectively targeting motor neurons in the brain and spinal cord. The reasons for differential motor neuron susceptibility remain elusive. We developed a stem cell-based motor neuron assay to study cell-autonomous mechanisms causing motor neuron degeneration, with implications for ALS. A small-molecule screen identified cyclopiazonic acid (CPA) as a stressor to which stem cell-derived motor neurons were more sensitive than interneurons. CPA induced endoplasmic reticulum stress and the unfolded protein response. Furthermore, CPA resulted in an accelerated degeneration of motor neurons expressing human superoxide dismutase 1 (hSOD1) carrying the ALS-causing G93A mutation, compared to motor neurons expressing wild-type hSOD1. A secondary screen identified compounds that alleviated CPA-mediated motor neuron degeneration: three kinase inhibitors and tauroursodeoxycholic acid (TUDCA), a bile acid derivative. The neuroprotective effects of these compounds were validated in human stem cell-derived motor neurons carrying a mutated SOD1 allele (hSOD1
Abstract 16790: A Step Forward to Our Understanding of the Mitral Valve Mechanics and Role in Patients With Hypertrophic Cardiomyopathy: a Real-time Three-dimensional Transesophageal Study
Authors: Erifili Venieri, Constantina Aggeli, Aris Anastasakis, Constantinos Ritsatos, Ioannis Felekos, Dimitrios Tousoulis
Journal: Circulation (2016)

Introduction/Purpose: There is growing evidence that the mitral apparatus in hypertrophic cardiomyopathy (HCM) has primary structural abnormalities. The objective of this study was the assessment o...
GW29-e0860 Best test to measure non-invasively the pulmonary artery wedge pressure and the left ventricular end diastolic pressure
Authors: Thach Nguyen, Thao Dang, Tu NT. Nguyen, Nguyen Phuoc Loc, Nguyen Bao Minh Nhu, Gianluca Rigatelli
Journal: Journal of the American College of Cardiology (2018)
Combined inhibition of MEK and PI3KCA pathway induces synergic antitumor activity in HER2 amplified human colorectal cancer models
Authors: V. Belli, N. Matrone, S. Napolitano, E. Martinelli, M.D. Castellone, L. Trusolino, E.F. Giunta, V. De Falco, N. Zanaletti, P.P. Vitiello, D. Ciardiello, M. Terminiello, F. Ciardiello, T. Troiani
Journal: Annals of Oncology (2018)
Negative Pressure Wound Therapy for Open Fractures—Reply
Authors: Matthew L. Costa
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The mechanosensitive ion channel Piezo2 mediates sensitivity to mechanical pain in mice
Authors: Swetha E. Murthy, Meaghan C. Loud, Ihab Daou, Kara L. Marshall, Frederick Schwaller, Johannes Kühnemund, Allain G. Francisco, William T. Keenan, Adrienne E. Dubin, Gary R. Lewin, Ardem Patapoutian
Journal: Science Translational Medicine (2018)

Piezo2 ion channels mediate mechanical allodynia in mice.
SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772)
Authors: Ganesh Raghu, Luca Richeldi, Bruno Crestani, Peter Wung, Raphael Bejuit, Corinne Esperet, Christian Antoni, Christina Soubrane
Journal: European Respiratory Journal (2018)

A phase 2b trial ( NCT02345070 ) was conducted to evaluate the efficacy and safety of two dose levels/regimens of SAR156597 (a bispecific IgG4 antibody that binds and neutralises both circulating interleukin-4 and interleukin-13), in comparison with placebo, administered to patients with idiopathic pulmonary fibrosis (IPF) over 52 weeks. DRI11772 was a multinational randomised double-blind placebo-controlled phase 2b trial. Patients aged &gt;40 years with a documented diagnosis of IPF received SAR156597 200 mg once every week (QW), SAR156597 200 mg once every 2 weeks (Q2W) or placebo, over 52 weeks. The primary efficacy end-point was absolute change from baseline in forced vital capacity (FVC) % predicted at 52 weeks. Of 327 randomised patients, 325 received treatment with placebo (n=109), SAR156597 Q2W (n=108) or SAR156597 QW (n=108). The mean change from baseline in FVC % pred at 52 weeks was –5.8%, –5.2% and –6.3% for the placebo, Q2W and QW arms, respectively (Q2W versus placebo, p=0.59; QW versus placebo, p=0.63). The safety profile observed in the three treatment arms was generally similar, although serious adverse events were more common in the QW arm than in the other arms. The DRI11772 study failed to demonstrate benefit of SAR156597 in the treatment of IPF.
Ebola: WHO expresses “very serious concern” about Congo outbreak
Authors: Sophie Arie
Journal: BMJ (2018)

An outbreak of Ebola virus disease in the Democratic Republic of the Congo is likely to spread to neighbouring countries but is not yet a global public health emergency, a committee of experts decided on 17 October.

The committee, convened by the World Health Organization, is “very seriously concerned” about an outbreak that has killed 139 people since it was declared on 1 August, and the situation is “likely to deteriorate significantly” if the international response does not intensify, said the committee chair, Robert Steffen.

Fighting among …
Peripheral Stem Cell Apheresis is Feasible Post 131Iodine-Metaiodobenzylguanidine-Therapy in High-Risk Neuroblastoma, but Results in Delayed Platelet Reconstitution
Authors: Kathelijne C.J.M. Kraal, Ilse Timmerman, Hannah M. Kansen, Cor van den Bos, Jozsef Zsiros, Henk van den Berg, Sebastiaan Somers, Eric Braakman, Annemarie M.L. Peek, Max M. van Noesel, C. Ellen van der Schoot, Marta Fiocco, Huib N. Caron, Carlijn Voermans, Godelieve A.M. Tytgat
Journal: Clinical Cancer Research (2018)

Targeted radiotherapy with 131iodine-meta-iodobenzylguanidine (131I-MIBG) is effective for neuroblastoma (NBL), although optimal scheduling during high-risk (HR) treatment is being investigated. We aimed to evaluate the feasibility of stem cell apheresis and study hematologic reconstitution after autologous stem cell transplantation (ASCT) in patients with HR-NBL treated with upfront 131I-MIBG-therapy.In two prospective multicenter cohort studies, newly diagnosed patients with HR-NBL were treated with two courses of 131I-MIBG-therapy, followed by an HR-induction protocol. Hematopoietic stem and progenitor cell (e.g., CD34+ cell) harvest yield, required number of apheresis sessions, and time to neutrophil (>0.5 × 109/L) and platelet (>20 × 109/L) reconstitution after ASCT were analyzed and compared with "chemotherapy-only"-treated patients. Moreover, harvested CD34+ cells were functionally (viability and clonogenic capacity) and phenotypically (CD33, CD41, and CD62L) tested before cryopreservation (n = 44) and/or after thawing (n = 19).Thirty-eight patients (47%) were treated with 131I-MIBG-therapy, 43 (53%) only with chemotherapy. Median cumulative 131I-MIBG dose/kg was 0.81 GBq (22.1 mCi). Median CD34+ cell harvest yield and apheresis days were comparable in both groups. Post ASCT, neutrophil recovery was similar (11 days vs. 10 days), whereas platelet recovery was delayed in 131I-MIBG- compared with chemotherapy-only-treated patients (29 days vs. 15 days, P = 0.037). Testing of harvested CD34+ cells revealed a reduced post-thaw viability in the 131I-MIBG-group. Moreover, the viable CD34+ population contained fewer cells expressing CD62L (L-selectin), a marker associated with rapid platelet recovery.Harvesting of CD34+ cells is feasible after 131I-MIBG. Platelet recovery after ASCT was delayed in 131I-MIBG-treated patients, possibly due to reinfusion of less viable and CD62L-expressing CD34+ cells, but without clinical complications. We provide evidence that peripheral stem cell apheresis is feasible after upfront 131I-MIBG-therapy in newly diagnosed patients with NBL. However, as the harvest of 131I-MIBG-treated patients contained lower viable CD34+ cell counts after thawing and platelet recovery after reinfusion was delayed, administration of 131I-MIBG after apheresis is preferred.
Which of afatinib and gefitinib/erlotinib is the better EGFR-TKI to be followed by osimertinib?
Authors: M. Tamiya, A. Tamiya, H. Suzuki, K. Nakahama, Y. Taniguchi, K. Kunimasa, M. Kimura, T. Inoue, K. Nishino, T. Hirashima, S. Atagi, F. Imamura, T. Kumagai
Journal: Annals of Oncology (2018)
Vaginal mesh implants: putting the relations between UK doctors and industry in plain sight
Authors: Jonathan Gornall
Journal: BMJ (2018)

Despite government guidance, it remains difficult to unpick industry funding of clinicians in the UK—and specialists in vaginal mesh treatment are no exception. <b>Jonathan Gornall</b> reports on the NHS surgeons, professional bodies, royal colleges, and medical conferences that benefit from corporate funding and how this financial involvement is hidden from patients
Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer who have poor performance status
Authors: Madoka Kimura, Kazumi Nishino, Fumio Imamura, Kazuhisa Nakashima, Toshiaki Takahashi, Takeya Sugimoto, Hiroaki Akamatsu, Nobuyuki Yamamoto, Haruko Daga, Hisao Imai, Tetsuhiko Taira, Yosuke Miyashita, Ryo Ko, Yasushi Hisamatsu, Haruyasu Murakami
Journal: Annals of Oncology (2018)
Pembrolizumab for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG): Phase II KEYNOTE-057 trial
Authors: R. de Wit, G.S. Kulkarni, E. Uchio, E.A. Singer, L. Krieger, P. Grivas, D. Bajorin, H.K. Seo, L. Mourey, A. Kamat, H. Nishiyama, E. Kapadia, K. Nam, T. Frenkl, A. Balar
Journal: Annals of Oncology (2018)
Abstract 17667: Quality of Life in Age- and Gender-Matched Patients with Preserved and Reduced Left Ventricular Ejection Fraction
Authors: Tialda Hoekstra, Ivonne Lesman-Leegte, Dirk Jan van Veldhuisen, Robert Sanderman, Tiny Jaarsma
Journal: Circulation (2010)

Background: Although the prognosis of heart failure (HF) patients with preserved ejection fraction (HF-PEF) seems as grim as the prognosis of HF patients with reduced ejection fraction (HF-REF), little is known about the impact of HF-PEF on quality of life (QoL) compared to HF-REF patients. Aim: To examine whether there are differences in QoL between patients with HF-REF and HF-PEF in a well defined HF population. Methods: Data were analyzed from 158 patients with HF-PEF (LVEF ≥40%) (41% female; age 72 ± 10; LVEF 51 ± 8%) and 158 age- and gender-matched patients with HF-REF (LVEF  100 pg/mL or N-terminal pro B-type Natriuretic Peptide-level (NT-proBNP) >400 pg/mL. QoL was assessed at 1 month after discharge of an initial HF hospitalization by Cantril's Ladder of Life, RAND-36 and the Minnesota Living with Heart Failure (MLwHF) questionnaire. Results: QoL between patients with HF-...
Standardising the psychosocial assessment of oncological patients at Donostia university hospital
Authors: E. Uranga, A. Valverde, M.A. Landa, M.J. Esnaola, L. Basterretxea, G. Agirre, O. Aizpurua, A. Barrio, M. Centeno, I. Delgado, G. Jauregui, L. Moreno, M. Murguiondo, J. San Francisco, H. Telleria
Journal: Annals of Oncology (2018)
A Core–Shell Nanoplatform for Synergistic Enhanced Sonodynamic Therapy of Hypoxic Tumor via Cascaded Strategy
Authors: Lei Wang, Mengya Niu, Cuixia Zheng, Hongjuan Zhao, Xiuxiu Niu, Li Li, Yujie Hu, Yingjie Zhang, Jinjin Shi, Zhenzhong Zhang
Journal: Advanced Healthcare Materials (2018)

Abstract Sonodynamic therapy (SDT) always causes tumor hypoxia aggravation which can induce malignant cell proliferation and drug resistance. To overcome these disadvantages, a cascaded drug delivery system (Lipo/HMME/ACF@MnO 2 ‐AS1411) is constructed for synergistic enhanced sonodynamic therapy. First, hematoporphyrin monomethyl ether (HMME) and acriflavine (ACF) are encapsulated in the lipid layers and the inner aqueous cores of the liposomes, respectively. Then the ultrathin manganese dioxide (MnO 2 ) nanosheets are coated on the surface of the liposomes by using KMnO 4 and polyethylene glycol through “one step reduction and modification” method. Furthermore, the nanoparticles are decorated with tumor‐targeting AS1411 aptamer through the phosphate groups on the DNA strand which can bind to Mn sites to obtain Lipo/HMME/ACF@MnO 2 ‐AS1411 delivery system. Herein, HMME can act as a sonosensitizer, and ACF is used to prevent the formation of HIF‐1α/HIF‐1β dimerization to overcome the negative effects after SDT. The Lipo/HMME/ACF@MnO 2 ‐AS1411 delivery system has multiple functions, including codelivery of HMME and ACF, pH/glutathione/ultrasound triple responses, synergistic cascaded enhancement of SDT, precise tumor‐targeting, and magnetic resonance imaging. The in vitro and in vivo results suggest that the Lipo/HMME/ACF@MnO 2 ‐AS1411 delivery system is a promising core–shell nanoplatform for synergistic enhancement of sonodynamic therapy, which can provide a new approach in the related research fields.
NCI-MATCH Arms N &amp; P: Phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (mut/del) or PTEN protein loss
Authors: F. Janku, O. Jegede, S.L. Puhalla, P. Konstantinopoulos, F. Meric-Bernstam, E.P. Mitchell, J.A. Zwiebel, L.M. McShane, S. Li, L.V. Rubinstein, L.A. Doyle, D. Patton, B.A. Conley, P.J. O’Dwyer, L.N. Harris, C. Arteaga, P.M. Williams, S.R. Hamilton, A.P. Chen, K.T. Flaherty
Journal: Annals of Oncology (2018)
One-view breast tomosynthesis versus two-view mammography in the Malmö Breast Tomosynthesis Screening Trial (MBTST): a prospective, population-based, diagnostic accuracy study
Authors: Sophia Zackrisson, Kristina Lång, Aldana Rosso, Kristin Johnson, Magnus Dustler, Daniel Förnvik, Hannie Förnvik, Hanna Sartor, Pontus Timberg, Anders Tingberg, Ingvar Andersson
Journal: The Lancet Oncology (2018)
Phase I clinical and translational evaluation of AZD6738 in combination with durvalumab in patients (pts) with lung or head and neck carcinoma
Authors: M. Krebs, J. Lopez, A. El-Khoueiry, Y.-J. Bang, S. Postel-Vinay, W. Abidah, S.-A. Im, L.T. Khoja, N. Standifer, G.N. Jones, P. Marco-Casanova, P. Frewer, A. Berges, A. Cheung, C. Stephens, B. Felicetti, E. Dean, A. Pierce, S. Hollingsworth
Journal: Annals of Oncology (2018)
Does a prior malignancy impact the survival of transitional cell carcinoma of the bladder?
Authors: Mohamad A. Alkhayat, Anas M. Saad, Mohamed M. Gad, Mariam A. Obaid, Sami Salahia, Remy Arwani, Muneer J. Al-Husseini
Journal: Annals of Oncology (2018)
Gender differences in trauma, shock and sepsis
Authors: Florian Bösch, Martin K. Angele, Irshad H. Chaudry
Journal: Military Medical Research (2018)

Despite efforts in prevention and intensive care, trauma and subsequent sepsis are still associated with a high mortality rate. Traumatic injury remains the main cause of death in people younger than 45 years and is thus a source of immense social and economic burden. In recent years, the knowledge concerning gender medicine has continuously increased. A number of studies have reported gender dimorphism in terms of response to trauma, shock and sepsis. However, the advantageous outcome following trauma-hemorrhage in females is not due only to sex. Rather, it is due to the prevailing hormonal milieu of the victim. In this respect, various experimental and clinical studies have demonstrated beneficial effects of estrogen for the central nervous system, the cardiopulmonary system, the liver, the kidneys, the immune system, and for the overall survival of the host. Nonetheless, there remains a gap between the bench and the bedside. This is most likely because clinical studies have not accounted for the estrus cycle. This review attempts to provide an overview of the current level of knowledge and highlights the most important organ systems responding to trauma, shock and sepsis. There continues to be a need for clinical studies on the prevailing hormonal milieu following trauma, shock and sepsis.
Biological, Legal, and Moral Definitions of Brain Death—Reply
Authors: Robert D. Truog
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
GW29-e1866 Chinese patent medicine for promoting blood circulation in treating stable angina pectoris of coronary heart disease: protocol for a systematic review and network meta-analysis
Authors: Dengfeng Kong, Wei Mu, Xiaochi Shi, Ge Li, Jingbo Zhai, Peng Tian, Yuhong Huang, Hongcai Shang
Journal: Journal of the American College of Cardiology (2018)
Outbreak of Neisseria meningitidis serogroup C outside the meningitis belt—Liberia, 2017: an epidemiological and laboratory investigation
Authors: Catherine H Bozio, Jeni Vuong, E Kainne Dokubo, Mosoka P Fallah, Lucy A McNamara, Caelin C Potts, John Doedeh, Miatta Gbanya, Adam C Retchless, Jaymin C Patel, Thomas A Clark, Henry Kohar, Thomas Nagbe, Peter Clement, Victoria Katawera, Nuha Mahmoud, Harouna M Djingarey, Anne Perrocheau, Dhamari Naidoo, Mardia Stone, Roseline N George, Desmond Williams, Alex Gasasira, Tolbert Nyenswah, Xin Wang, LeAnne M Fox, Youhn Konway, Samson Q Wiah, Vivian Doedeh, Umaru Bao, George Senneh, Lawrence Gorwor, Philemon Gonotee, Thomas Paasewe, George Tamatai, James Yarkeh, Samuel Smith, Annette Brima-Davis, George Dauda, Thomas Monger, Leleh W Gornor-Pewu, Siafa Lombeh, Himiede W Wilson, Mark Korvayan, Nathaniel Dovillie, Ralph Jetoh, Fahn Taweh, Yatta Vera Walker, Patrick Hardy, Maxwell Freeman, Geraldine George, Garrison Kerwillain, Sylvester Toe, Emmanuel Ghartey, Lawrence Larway, Dedesco Gweh, Denise Allen, Suzanne Friesen, Gulu Gwesa, Carl Kinkade, Mulbah Reed, Arthur Chang, Josiah George, Joshua Schier, Jerry Thomas, Maureen H Diaz, Laurel T Jenkins, Barbara E Mahon, Susanna E Schmink, Sandeep J Joseph, Jessica L Waller, Melissa J Whaley, Jonas M Winchell, Ray R Arthur, Serena Fuller, Kira Christian, John T Redd, Kwuakuan D M Yealue, Jeremias Naiene, Joseph Asamoah Frimpong, Maame Amo-Addae, Olayinka Stephen, Anne Von Gottberg, Muhamed Taha
Journal: The Lancet Infectious Diseases (2018)
Actionable mutations and overall survival in 3,211 patients with cancer: The Hellenic cooperative oncology group precision medicine initiative
Authors: E. Fountzila, V. Kotoula, G.-A. Koliou, E. Giannoulatou, H. Gogas, C. Papadimitriou, I.S. Tikas, K. Papadopoulou, F. Zagouri, C. Christodoulou, A. Koutras, E. Razis, P. Papakostas, E. Samantas, G. Aravantinos, A. Psyrri, D.G. Pectasides, A. Futreal, A.-M. Tsimberidou, G. Fountzilas
Journal: Annals of Oncology (2018)
Abstract 17758: Heart-Lung Transplantation Outcomes in Adult Congenital Heart Disease
Authors: Asma M Khan, Irene D Lytrivi, Hari Rajagopal, Lisa M Nicholson, Elfriede Pahl
Journal: Circulation (2016)

Introduction: Heart-lung transplantation (HLT) may be indicated in adult congenital heart disease patients (ACHD) with or without Eisenmenger syndrome (ES) with end-stage heart and lung disease. Pr...